ABG
RARE icon

Ally Bridge Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ally Bridge Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-185,261
Closed -$8.58M – 33
2022
Q4 		$8.58M Sell
185,261
-31,814
-15% -$1.25M 8.35% 1
2022
Q3 		$8.99M Buy
+217,075
New +$11.2M 5.93% 2

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Ally Bridge Group's RARE Position: Q1 2023 in Review

Ally Bridge Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2023, closing a stake of 185,261 shares — an estimated $8.58M sold.

Ally Bridge Group first reported a position in RARE in Q3 2022 and held it in 2 quarters. The position peaked at $8.99M in Q3 2022. 228 funds tracked by Wall St. Rank hold RARE as of Q1 2023.

  • Ally Bridge Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Ally Bridge Group sold 185,261 Ultragenyx Pharmaceutical shares in Q1 2023, an estimated $8.58M.
  • Ally Bridge Group first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and held it in 2 quarters.
  • Ally Bridge Group's Ultragenyx Pharmaceutical position peaked at $8.99M in Q3 2022.
  • 228 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.